{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:33:28Z","timestamp":1777376008982,"version":"3.51.4"},"reference-count":223,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["DEC-2014\/15\/D\/NZ7\/01789"],"award-info":[{"award-number":["DEC-2014\/15\/D\/NZ7\/01789"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005632","name":"Narodowe Centrum Bada\u0144 i Rozwoju","doi-asserted-by":"publisher","award":["POIR.01.01.01-00-0108\/17)."],"award-info":[{"award-number":["POIR.01.01.01-00-0108\/17)."]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40263-020-00707-7","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T20:02:47Z","timestamp":1581537767000},"page":"243-268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4948-6617","authenticated-orcid":false,"given":"Monika","family":"Marcinkowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"\u015aniecikowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Fajkis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Pa\u015bko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weronika","family":"Franczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcin","family":"Ko\u0142aczkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"key":"707_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00019442-200002000-00004","volume":"8","author":"DV Jeste","year":"2000","unstructured":"Jeste DV, Finkel SI. Psychosis of Alzheimer\u2019s disease and related dementias: diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000;8:29\u201334.","journal-title":"Am J Geriatr Psychiatry."},{"key":"707_CR2","unstructured":"Alzforum. https:\/\/www.alzforum.org\/papers\/uber-eine-eigenartige-erkrankung-der-hirnrinde\/en. Accessed 16 Dec 2019."},{"key":"707_CR3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.31887\/DCNS.2003.5.1\/fmuellerspahn","volume":"5","author":"F M\u00fcller-Spahn","year":"2003","unstructured":"M\u00fcller-Spahn F. Behavioral disturbances in dementia. Dialog Clin Neurosci. 2003;5:49\u201359.","journal-title":"Dialog Clin Neurosci."},{"key":"707_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fneur.2012.00073","volume":"3","author":"J Cerejeira","year":"2012","unstructured":"Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73.","journal-title":"Front Neurol."},{"key":"707_CR5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1017\/S1041610216001654","volume":"29","author":"S Toot","year":"2017","unstructured":"Toot S, Swinson T, Devine M, Challis D, Orrell M. Causes of nursing home placement for older people with dementia: a systematic review and meta-analysis. Int Psychogeriatr. 2017;29:195\u2013208.","journal-title":"Int Psychogeriatr"},{"key":"707_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.psc.2017.10.010","volume":"41","author":"LB Gerlach","year":"2018","unstructured":"Gerlach LB, Kales HC. Managing behavioral and psychological symptoms of dementia. Psychiatr Clin North Am. 2018;41:127\u201339.","journal-title":"Psychiatr Clin North Am"},{"key":"707_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/2040622316658463","volume":"7","author":"RR Tampi","year":"2016","unstructured":"Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7:229\u201345.","journal-title":"Ther Adv Chronic Dis."},{"key":"707_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.euroneuro.2017.01.002","volume":"27","author":"MR Farlow","year":"2017","unstructured":"Farlow MR, Shamliyan TA. Benefits and harms of atypical antipsychotics for agitation in adults with dementia. Eur Neuropsychopharmacol. 2017;27:217\u201331.","journal-title":"Eur Neuropsychopharmacol"},{"key":"707_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/bmj.c4245","volume":"341","author":"C Parker","year":"2010","unstructured":"Parker C, Coupland C, Hippisley-Cox J. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ. 2010;341:42\u20135.","journal-title":"BMJ"},{"key":"707_CR10","unstructured":"FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioral disturbances. http:\/\/psychrights.org\/drugs\/FDAantipsychotics4elderlywarning.htm. Accessed 16 Dec 2019."},{"key":"707_CR11","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","volume":"294","author":"LS Schneider","year":"2005","unstructured":"Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934\u201343.","journal-title":"JAMA"},{"key":"707_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1176\/appi.ajp.2015.173501","volume":"173","author":"VI Reus","year":"2016","unstructured":"Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173:543\u20136.","journal-title":"Am J Psychiatry"},{"key":"707_CR13","doi-asserted-by":"crossref","unstructured":"Dupuis DS, Mannoury la Cour C, Chaput C, Verri\u00e8le L, Lavielle G, Millan MJ. Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT6 receptors: a comparative study of coupling to G alpha s. Eur J Pharmacol. 2008;588:170\u20137.","DOI":"10.1016\/j.ejphar.2008.04.039"},{"key":"707_CR14","unstructured":"NICE. Dementia: supporting people with dementia and their carers in health and social care. https:\/\/www.nice.org.uk\/guidance\/cg42. Accessed 16 Dec 2019."},{"key":"707_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s00391-016-1176-0","volume":"50","author":"W Hewer","year":"2017","unstructured":"Hewer W, Thomas C. Treatment with psychotropic agents in patients with dementia and delirium: gap between guideline recommendations and treatment practice. Z Gerontol Geriatr. 2017;50:106\u201314.","journal-title":"Z Gerontol Geriatr"},{"key":"707_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1017\/S1041610218000534","volume":"31","author":"HC Kales","year":"2019","unstructured":"Kales HC, Lyketsos CG, Miller EM, Ballard C. Management of behavioral and psychological symptoms in people with Alzheimer\u2019s disease: an international Delphi consensus. Int Psychogeriatr. 2019;31:83\u201390.","journal-title":"Int Psychogeriatr"},{"key":"707_CR17","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1111\/j.1471-4159.2010.06719.x","volume":"113","author":"HD VanGuilder","year":"2010","unstructured":"VanGuilder HD, Yan H, Farley JA, Sonntag WE, Freeman WM. Aging alters the expression of neurotransmission-regulating proteins in the hippocampal synaptoproteome. J Neurochem. 2010;113:1577\u201388.","journal-title":"J Neurochem"},{"key":"707_CR18","first-page":"395","volume":"8","author":"A Choudhury","year":"2018","unstructured":"Choudhury A, Sahu T, Ramanujam PL, Banerjee AK, Chakraborty I, Kumar AR, et al. Neurochemicals, behaviours and psychiatric perspectives of neurological diseases. Neuropsychiatry. 2018;8:395\u2013424.","journal-title":"Neuropsychiatry."},{"key":"707_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13073-014-0052-z","volume":"6","author":"I Vogt","year":"2014","unstructured":"Vogt I, Prinz J, Campillos M. Molecularly and clinically related drugs and diseases are enriched in phenotypically similar drug-disease pairs. Genome Med. 2014;6:52.","journal-title":"Genome Med."},{"key":"707_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40266-016-0434-6","volume":"34","author":"AH Ford","year":"2017","unstructured":"Ford AH, Almeida OP. Management of depression in patients with dementia: is pharmacological treatment justified? Drugs Aging. 2017;34:89\u201395.","journal-title":"Drugs Aging"},{"key":"707_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2147\/CIA.S1698","volume":"2","author":"EC Hersch","year":"2007","unstructured":"Hersch EC, Falzgraf S. Management of the behavioral and psychological symptoms of dementia. Clin Interv Aging. 2007;2:611\u201321.","journal-title":"Clin Interv Aging"},{"key":"707_CR22","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/brain\/awx327","volume":"141","author":"AG Murley","year":"2018","unstructured":"Murley AG, Rowe JB. Neurotransmitter deficits from frontotemporal lobar degeneration. Brain. 2018;141:1263\u201385.","journal-title":"Brain"},{"key":"707_CR23","doi-asserted-by":"crossref","unstructured":"Bondareff W. Neuropathology of psychotic symptoms in Alzheimer\u2019s disease. Int Psychogeriatr. 1996;8(Suppl. 3):233\u20137 (discussion 269\u201372).","DOI":"10.1017\/S1041610297003402"},{"key":"707_CR24","first-page":"219","volume":"83","author":"GS Zubenko","year":"1996","unstructured":"Zubenko GS. Clinicopathologic and neurochemical correlates of major depression and psychosis in primary dementia. Int Psychogeriatr. 1996;83:219\u201323.","journal-title":"Int Psychogeriatr"},{"key":"707_CR25","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0893-133X(97)00194-2","volume":"18","author":"CC Meltzer","year":"1998","unstructured":"Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY, et al. Serotonin in aging, late-life depression, and Alzheimer\u2019s disease: the emerging role of functional imaging. Neuropsychopharmacology. 1998;18:407\u201330.","journal-title":"Neuropsychopharmacology."},{"key":"707_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1471-2202-7-36","volume":"7","author":"DE Lorke","year":"2006","unstructured":"Lorke DE, Lu G, Cho E, Yew DT. Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci. 2006;7:36.","journal-title":"BMC Neurosci."},{"key":"707_CR27","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1093\/hmg\/7.9.1507","volume":"7","author":"C Holmes","year":"1998","unstructured":"Holmes C, Arranz MJ, Powell JF, Collier DA, Lovestone S. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer\u2019s disease. Hum Mol Genet. 1998;7:1507\u20139.","journal-title":"Hum Mol Genet"},{"key":"707_CR28","first-page":"435","volume":"22","author":"SN Gomperts","year":"2016","unstructured":"Gomperts SN. Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia. Contin Minneap Minn. 2016;22:435\u201363.","journal-title":"Contin Minneap Minn."},{"key":"707_CR29","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/JGP.0b013e3181953b9a","volume":"17","author":"D Tsuang","year":"2009","unstructured":"Tsuang D, Larson EB, Bolen E, Thompson ML, Peskind E, Bowen J, et al. Visual hallucinations in dementia: a prospective community-based study with autopsy. Am J Geriatr Psychiatry. 2009;17:317\u201323.","journal-title":"Am J Geriatr Psychiatry."},{"key":"707_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s10072-007-0794-0","volume":"28","author":"E Sinforiani","year":"2007","unstructured":"Sinforiani E, Terzaghi M, Pasotti C, Zucchella C, Zambrelli E, Manni R. Hallucinations and sleep-wake cycle in Alzheimer\u2019s disease: a questionnaire-based study in 218 patients. Neurol Sci. 2007;28:96\u20139.","journal-title":"Neurol Sci."},{"key":"707_CR31","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/gps.1409","volume":"20","author":"H Brodaty","year":"2005","unstructured":"Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al. Risperidone for psychosis of Alzheimer\u2019s disease and mixed dementia: results of a double-blind, placebo-controlled trial. Int J Geriatr Psychiatry. 2005;20:1153\u20137.","journal-title":"Int J Geriatr Psychiatry."},{"key":"707_CR32","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1001\/archneur.58.9.1425","volume":"58","author":"DL Sukonick","year":"2001","unstructured":"Sukonick DL, Pollock BG, Sweet RA, Mulsant BH, Rosen J, Klunk WE, et al. The 5-HTTPR*S\/*L polymorphism and aggressive behavior in Alzheimer disease. Arch Neurol. 2001;58:1425\u20138.","journal-title":"Arch Neurol"},{"key":"707_CR33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1017\/S1041610201007827","volume":"13","author":"RA Sweet","year":"2001","unstructured":"Sweet RA, Pollock BG, Sukonick DL, Mulsant BH, Rosen J, Klunk WE, et al. The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease. Int Psychogeriatr. 2001;13:401\u20139.","journal-title":"Int Psychogeriatr"},{"key":"707_CR34","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0006-8993(03)02554-X","volume":"974","author":"MKP Lai","year":"2003","unstructured":"Lai MKP, Tsang SWY, Francis PT, Esiri MM, Keene J, Hope T, et al. Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res. 2003;974:82\u20137.","journal-title":"Brain Res"},{"key":"707_CR35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fnins.2015.00220","volume":"9","author":"M Gannon","year":"2015","unstructured":"Gannon M, Che P, Chen Y, Jiao K, Roberson ED, Wang Q. Noradrenergic dysfunction in Alzheimer\u2019s disease. Front Neurosci. 2015;9:220.","journal-title":"Front Neurosci."},{"key":"707_CR36","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/archneur.55.10.1335","volume":"55","author":"RA Sweet","year":"1998","unstructured":"Sweet RA, Nimgaonkar VL, Kamboh MI, Lopez OL, Zhang F, DeKosky ST. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. Arch Neurol. 1998;55:1335\u201340.","journal-title":"Arch Neurol"},{"key":"707_CR37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.neuropharm.2013.07.013","volume":"75","author":"M Rodriguez-Arias","year":"2013","unstructured":"Rodriguez-Arias M, Navarrete F, Daza-Losada M, Navarro D, Aguilar MA, Berbel P, et al. CB1 cannabinoid receptor-mediated aggressive behavior. Neuropharmacology. 2013;75:172\u201380.","journal-title":"Neuropharmacology"},{"key":"707_CR38","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.euroneuro.2013.10.002","volume":"24","author":"R Ahmad","year":"2014","unstructured":"Ahmad R, Goffin K, Van den Stock J, De Winter F-L, Cleeren E, Bormans G, et al. In vivo type 1 cannabinoid receptor availability in Alzheimer\u2019s disease. Eur Neuropsychopharmacol. 2014;24:242\u201350.","journal-title":"Eur Neuropsychopharmacol"},{"key":"707_CR39","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/brain\/awr046","volume":"134","author":"J Mulder","year":"2011","unstructured":"Mulder J, Zilberter M, Pasquar\u00e9 SJ, Alp\u00e1r A, Schulte G, Ferreira SG, et al. Molecular reorganization of endocannabinoid signalling in Alzheimer\u2019s disease. Brain J Neurol. 2011;134:1041\u201360.","journal-title":"Brain J Neurol."},{"key":"707_CR40","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.3233\/JAD-160763","volume":"57","author":"R Wang","year":"2017","unstructured":"Wang R, Reddy PH. Role of glutamate and NMDA receptors in Alzheimer\u2019s disease. J Alzheimers Dis. 2017;57:1041\u20138.","journal-title":"J Alzheimers Dis."},{"key":"707_CR41","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.pbb.2011.08.008","volume":"100","author":"MJ Niciu","year":"2012","unstructured":"Niciu MJ, Kelmendi B, Sanacora G. Overview of glutamatergic neurotransmission in the nervous system. Pharmacol Biochem Behav. 2012;100:656\u201364.","journal-title":"Pharmacol Biochem Behav"},{"key":"707_CR42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnmol.2019.00020","volume":"12","author":"R Crupi","year":"2019","unstructured":"Crupi R, Impellizzeri D, Cuzzocrea S. Role of metabotropic glutamate receptors in neurological disorders. Front Mol Neurosci. 2019;12:20.","journal-title":"Front Mol Neurosci."},{"key":"707_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2174\/157015912799362805","volume":"10","author":"N Hovels\u00f8","year":"2012","unstructured":"Hovels\u00f8 N, Sotty F, Montezinho LP, Pinheiro PS, Herrik KF, M\u00f8rk A. Therapeutic potential of metabotropic glutamate receptor modulators. Curr Neuropharmacol. 2012;10:12\u201348.","journal-title":"Curr Neuropharmacol"},{"key":"707_CR44","doi-asserted-by":"crossref","unstructured":"Bratek E, Ziembowicz A, Bronisz A, Salinska E. The activation of group II metabotropic glutamate receptors protects neonatal rat brains from oxidative stress injury after hypoxia-ischemia. PLoS One. 2018;13(7).","DOI":"10.1371\/journal.pone.0200933"},{"key":"707_CR45","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nbd.2004.07.016","volume":"17","author":"GG Far\u00edas","year":"2004","unstructured":"Far\u00edas GG, Godoy JA, Hern\u00e1ndez F, Avila J, Fisher A, Inestrosa NC. M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity: a role for Wnt signaling pathway. Neurobiol Dis. 2004;17:337\u201348.","journal-title":"Neurobiol Dis"},{"key":"707_CR46","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1527-3458.2003.tb00247.x","volume":"9","author":"NR Mirza","year":"2003","unstructured":"Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. 2003;9:159\u201386.","journal-title":"CNS Drug Rev"},{"key":"707_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40263-016-0399-3","volume":"31","author":"H Ferrero","year":"2017","unstructured":"Ferrero H, Solas M, Francis PT, Ramirez MJ. Serotonin 5-HT6 receptor antagonists in Alzheimer\u2019s disease: therapeutic rationale and current development status. CNS Drugs. 2017;31:19\u201332.","journal-title":"CNS Drugs"},{"key":"707_CR48","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/j.1460-9568.2006.05003.x","volume":"24","author":"B Marcos","year":"2006","unstructured":"Marcos B, Gil-Bea FJ, Hirst WD, Garc\u00eda-Alloza M, Ram\u00edrez MJ. Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release. Eur J Neurosci. 2006;24:1299\u2013306.","journal-title":"Eur J Neurosci"},{"key":"707_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.trci.2018.03.009","volume":"4","author":"J Cummings","year":"2018","unstructured":"Cummings J, Lee G, Ritter A, Zhong K. Alzheimer\u2019s disease drug development pipeline: 2018. Alzheimers Dement Transl Res Clin Interv. 2018;4:195\u2013214.","journal-title":"Alzheimers Dement Transl Res Clin Interv."},{"key":"707_CR50","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cct.2018.05.019","volume":"71","author":"DP Devanand","year":"2018","unstructured":"Devanand DP, Strickler JG, Huey ED, Crocco E, Forester BP, Husain MM, et al. Lithium treatment for agitation in Alzheimer\u2019s disease (Lit-AD): clinical rationale and study design. Contemp Clin Trials. 2018;71:33\u20139.","journal-title":"Contemp Clin Trials."},{"key":"707_CR51","unstructured":"ClinicalTrials.gov. A two part study to assess safety, PK, PD, and food effect of oral HTL0016878. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03244228. Accessed 20 Aug 2019."},{"key":"707_CR52","unstructured":"Amarantus announces positive phase 2 data for eltoprazine in Alzheimer\u2019s aggression. Available from: https:\/\/www.amarantus.com\/news\/press-releases\/detail\/2033\/amarantus-announces-positive-phase-2-data-for-eltoprazine. Accessed 20 Aug 2019."},{"key":"707_CR53","unstructured":"ClinicalTrials.gov. A study of MP-101 in dementia-related psychosis and\/or agitation and aggression. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03044249. Accessed 20 Aug 2019."},{"issue":"1\u20132","key":"707_CR54","first-page":"47","volume":"4","author":"MJ Davey","year":"1982","unstructured":"Davey MJ. The pharmacology of prazosin, an alpha 1-adrenoceptor antagonist and the basis for its use in the treatment of essential hypertension. Clin Exp Hypertens A. 1982;4(1\u20132):47\u201359.","journal-title":"Clin Exp Hypertens A."},{"key":"707_CR55","unstructured":"ClinicalTrials.gov. Prazosin for agitation in Alzheimer\u2019s disease. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03710642. Accessed 20 Aug 2019."},{"key":"707_CR56","unstructured":"ClinicalTrials.gov. A study of pimavanserin for the treatment of agitation and aggression in subjects with Alzheimer\u2019s disease. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03118947. Accessed 20 Aug 2019."},{"key":"707_CR57","unstructured":"ClinicalTrials.gov. A study of the safety and efficacy of pimavanserin in patients with Alzheimer\u2019s disease psychosis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02035553. Accessed 20 Aug 2019."},{"key":"707_CR58","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","volume":"17","author":"C Ballard","year":"2018","unstructured":"Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer\u2019s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 2018;17:213\u201322.","journal-title":"Lancet Neurol."},{"key":"707_CR59","unstructured":"ClinicalTrials.gov. Safety and efficacy of nabilone in Alzheimer\u2019s disease. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02351882. Accessed 20 Aug 2019."},{"key":"707_CR60","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.jalz.2018.06.2871","volume":"14","author":"KL Lanctot","year":"2018","unstructured":"Lanctot KL, Ruthirakuhan M, Gallagher D, Sherman C, Abraham EH, Verhoeff NPLG, et al. Nabilone significantly improves agitation\/adression in patients with moderate-to-severe AD: preliminary results of a placebo-controlled, double-blind, cross-over trial. Alzheimers Dement. 2018;14:1385.","journal-title":"Alzheimers Dement."},{"issue":"11","key":"707_CR61","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jagp.2019.05.002","volume":"27","author":"N Herrmann","year":"2019","unstructured":"Herrmann N, Ruthirakuhan M, Gallagher D, Verhoeff NPLG, Kiss A, Black SE, et al. Randomized placebo-controlled trial of nabilone for agitation in Alzheimer\u2019s disease. Am J Geriatr Psychiatry. 2019;27(11):1161\u201373.","journal-title":"Am J Geriatr Psychiatry."},{"key":"707_CR62","unstructured":"ClinicalTrials.gov. Addressing dementia via agitation-centered evaluation. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03226522. Accessed 20 Aug 2019."},{"key":"707_CR63","unstructured":"Axsome Therapeutics, Inc. Axsome Therapeutics announces positive outcome of interim analysis of ADVANCE-1 phase 2\/3 trial of AXS-05 in Alzheimer\u2019s disease agitation. GlobeNewswire News Room. 2018. http:\/\/www.globenewswire.com\/news-release\/2018\/12\/10\/1664251\/0\/en\/Axsome-Therapeutics-Announces-Positive-Outcome-of-Interim-Analysis-of-ADVANCE-1-Phase-2-3-Trial-of-AXS-05-in-Alzheimer-s-Disease-Agitation.html. Accessed 20 Aug 2019."},{"key":"707_CR64","unstructured":"ClinicalTrials.gov. Relapse prevention study of pimavanserin in dementia-related psychosis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03325556. Accessed 20 Aug 2019."},{"key":"707_CR65","unstructured":"Clinical Trials Register. Search for 2017-004439-36. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2017-004439-36. Accessed 16 Dec 2019."},{"key":"707_CR66","unstructured":"Clinical Trials Register. Search for 2017-002227-13. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2017-002227-13. Accessed 16 Dec 2019."},{"key":"707_CR67","unstructured":"ClinicalTrials.gov. Escitalopram for agitation in Alzheimer\u2019s disease. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03108846. Accessed 20 Aug 2019."},{"key":"707_CR68","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1124\/jpet.114.213793","volume":"350","author":"K Maeda","year":"2014","unstructured":"Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:589\u2013604.","journal-title":"J Pharmacol Exp Ther"},{"key":"707_CR69","unstructured":"ClinicalTrials.gov. Brexpiprazole for the long-term treatment of patients with agitation associated with dementia of the Alzheimer\u2019s type. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03724942. Accessed 20 Aug 2019."},{"key":"707_CR70","unstructured":"Clinical Trials Register. Search for 2017-003940-19. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2017-003940-19. Accessed 16 Dec 2019."},{"key":"707_CR71","unstructured":"Clinical Trials Register. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-002783-88\/BG. Accessed 16 Dec 2019."},{"key":"707_CR72","first-page":"201712000006","volume":"4","author":"L Zhang","year":"2018","unstructured":"Zhang L, Hendrick JP. The presynaptic D2 partial agonist lumateperone acts as a postsynaptic D2 antagonist. Matters. 2018;4:201712000006.","journal-title":"Matters."},{"issue":"54","key":"707_CR73","first-page":"713","volume":"2018","author":"B Kumar","year":"1998","unstructured":"Kumar B, Kuhad A, Kuhad A. Lumateperone: a new treatment approach for neuropsychiatric disorders. Drugs Today Barc Spain. 1998;2018(54):713\u20139.","journal-title":"Drugs Today Barc Spain"},{"key":"707_CR74","unstructured":"ClinicalTrials.gov. Long term, extension study of the safety and efficacy of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer\u2019s type. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02446132. Accessed 20 Aug 2019."},{"key":"707_CR75","unstructured":"ClinicalTrials.gov. Study of mirtazapine for agitation in dementia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03031184. Accessed 20 Aug 2019."},{"key":"707_CR76","unstructured":"ClinicalTrials.gov. Nighttime agitation and restless legs syndrome in people with Alzheimer\u2019s disease. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03082755. Accessed 20 Aug 2019."},{"key":"707_CR77","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.2174\/092986707781368450","volume":"14","author":"A Serretti","year":"2007","unstructured":"Serretti A, Drago A, De Ronchi D. HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr Med Chem. 2007;14:2053\u201369.","journal-title":"Curr Med Chem"},{"issue":"1","key":"707_CR78","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10522-012-9406-3","volume":"14","author":"S Fidalgo","year":"2013","unstructured":"Fidalgo S, Ivanov DK, Wood SH. Serotonin: from top to bottom. Biogerontology. 2013;14(1):21\u201345.","journal-title":"Biogerontology"},{"key":"707_CR79","unstructured":"ACADIA Pharmaceuticals announces positive top-line results from phase II study of pimavanserin for Alzheimer\u2019s disease psychosis. 2016. https:\/\/www.businesswire.com\/news\/home\/20161220005379\/en\/ACADIA-Pharmaceuticals-Announces-Positive-Top-Line-Results-Phase. Accessed 16 Dec 2019."},{"key":"707_CR80","unstructured":"Business Wire. ACADIA Pharmaceuticals initiates phase III study of pimavanserin in dementia-related psychosis. https:\/\/www.businesswire.com\/news\/home\/20171004006297\/en\/ACADIA-Pharmaceuticals-Initiates-Phase-III-Study-Pimavanserin. Accessed 16 Dec 2019."},{"key":"707_CR81","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1007\/s11064-014-1293-3","volume":"39","author":"U Hacksell","year":"2014","unstructured":"Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H. On the discovery and development of pimavanserin: a novel drug candidate for Parkinson\u2019s psychosis. Neurochem Res. 2014;39:2008\u201317.","journal-title":"Neurochem Res"},{"key":"707_CR82","first-page":"268","volume":"299","author":"DM Weiner","year":"2001","unstructured":"Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, et al. 5-Hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther. 2001;299:268\u201376.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"707_CR83","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1017\/S1461145707007869","volume":"11","author":"AL Nordstrom","year":"2008","unstructured":"Nordstrom AL, Mansson M, Jovanovic H, Karlsson P, Halldin C, et al. PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. Int J Neuropsychopharmacol. 2008;11(2):163\u201371.","journal-title":"Int J Neuropsychopharmacol"},{"key":"707_CR84","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1124\/jpet.105.097006","volume":"317","author":"KE Vanover","year":"2006","unstructured":"Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, et al. Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N\u2032-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther. 2006;317:910\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"707_CR85","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/FBP.0b013e3283566082","volume":"23","author":"DL Price","year":"2012","unstructured":"Price DL, Bonhaus DW, McFarland K. Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer\u2019s disease. Behav Pharmacol. 2012;23:426\u201333.","journal-title":"Behav Pharmacol"},{"key":"707_CR86","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383:533\u201340.","journal-title":"Lancet"},{"key":"707_CR87","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/gps.930100607","volume":"10","author":"CG Ballard","year":"1995","unstructured":"Ballard CG, Saad K, Patel A, Gahir M, Solis M, Coope B, et al. The prevalence and phenomenology of psychotic symptoms in dementia sufferers. Int J Geriatr Psychiatry. 1995;10:477\u201385.","journal-title":"Int J Geriatr Psychiatry."},{"key":"707_CR88","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1017\/S1461145706007000","volume":"10","author":"S Sato","year":"2007","unstructured":"Sato S, Mizukami K, Asada T. A preliminary open-label study of 5-HT1A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia. Int J Neuropsychopharmacol. 2007;10:281\u20133.","journal-title":"Int J Neuropsychopharmacol"},{"key":"707_CR89","doi-asserted-by":"crossref","unstructured":"Cantillon M, Brunswick R, Molina D, Bahro M. Buspirone vs. haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer\u2019s disease. Am J Geriatr Psychiatry. 1996;4:263\u20137.","DOI":"10.1097\/00019442-199622430-00011"},{"key":"707_CR90","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0140-6736(93)92660-L","volume":"341","author":"J Tiihonen","year":"1993","unstructured":"Tiihonen J, Hakola P, Paanila J, Turtiainen M. Eltoprazine for aggression in schizophrenia and mental retardation. Lancet. 1993;341:307.","journal-title":"Lancet"},{"key":"707_CR91","unstructured":"Amarantus BioScience Holdings, Inc. (AMBS). Eltoprazine. https:\/\/www.amarantus.com\/therapeutics-pipeline\/therapeutics\/eltoprazine. Accessed 20 Aug 2019."},{"key":"707_CR92","unstructured":"ClinicalTrials.gov. A study of efficacy and safety of eltoprazine HCl for treating levodopa-induced dyskinesia in Parkinson\u2019s disease patients. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02439125. Accessed 20 Aug 2019."},{"key":"707_CR93","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1365-2125.1990.tb05454.x","volume":"30","author":"M Raghoebar","year":"1990","unstructured":"Raghoebar M, Mak M, Cournot A, et al. Pharmacokinetics of eltoprazine inhealthy male subjects after single dose oral and intravenous administration. Br J Clin Pharmacol. 1990;30:879\u201383.","journal-title":"Br J Clin Pharmacol"},{"issue":"2\u20133","key":"707_CR94","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0014-2999(92)90348-8","volume":"212","author":"J Mos","year":"1992","unstructured":"Mos J, Olivier B, Poth M, van Aken H. The effects of intraventricular administration of eltoprazine, 1-(3-trifluoromethylphenyl)piperazine hydrochloride and 8-hydroxy-2-(di-n-propylamino)tetralin on resident intruder aggression in the rat. Eur J Pharmacol. 1992;212(2\u20133):295\u20138.","journal-title":"Eur J Pharmacol"},{"key":"707_CR95","unstructured":"Monn J, Prieto L, Taboada Martinez L, Montero Salgado C, Shaw BW. Mglu2 agonists. Patent WO2011084437, 2011."},{"key":"707_CR96","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0014-2999(92)90348-8","volume":"212","author":"J Mos","year":"1992","unstructured":"Mos J, Olivier B, Poth M, van Aken H. The effects of intraventricular administration of eltoprazine, 1-(3-trifluoromethylphenyl)piperazine hydrochloride and 8-hydroxy-2-(di-n-propylamino)tetralin on resident intruder aggression in the rat. Eur J Pharmacol. 1992;212:295\u20138.","journal-title":"Eur J Pharmacol"},{"key":"707_CR97","doi-asserted-by":"crossref","unstructured":"Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, et al. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson\u2019s disease: a dose-finding study. Brain J Neurol. 2015;138:963\u201373.","DOI":"10.1093\/brain\/awu409"},{"key":"707_CR98","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1515\/DMDI.1990.8.1-2.85","volume":"8","author":"J Schipper","year":"1990","unstructured":"Schipper J, Tulp MT, Sijbesma H. Neurochemical profile of eltoprazine. Drug Metabol Drug Interact. 1990;8:85\u2013114.","journal-title":"Drug Metabol Drug Interact."},{"key":"707_CR99","doi-asserted-by":"publisher","first-page":"14968","DOI":"10.1073\/pnas.1107411108","volume":"108","author":"JR Cirrito","year":"2011","unstructured":"Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, et al. Serotonin signaling is associated with lower amyloid-\u03b2 levels and plaques in transgenic mice and humans. Proc Natl Acad Sci USA. 2011;108:14968\u201373.","journal-title":"Proc Natl Acad Sci USA."},{"key":"707_CR100","first-page":"236","volume":"6","author":"YI Sheline","year":"2014","unstructured":"Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, et al. An antidepressant decreases CSF A\u03b2 production in healthy individuals and in transgenic AD mice. Sci Transl Med. 2014;6:236\u201344.","journal-title":"Sci Transl Med."},{"key":"707_CR101","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1126\/science.1083328","volume":"301","author":"L Santarelli","year":"2003","unstructured":"Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805\u20139.","journal-title":"Science"},{"key":"707_CR102","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1176\/appi.ajp.159.3.460","volume":"159","author":"BG Pollock","year":"2002","unstructured":"Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159:460\u20135.","journal-title":"Am J Psychiatry"},{"key":"707_CR103","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.2014.93","volume":"311","author":"AP Porsteinsson","year":"2014","unstructured":"Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311:682\u201391.","journal-title":"JAMA"},{"key":"707_CR104","unstructured":"US FDA. FDA drug safety communication: abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). 2018. http:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-abnormal-heart-rhythms-associated-high-doses-celexa-citalopram. Accessed 20 Aug 2019."},{"key":"707_CR105","doi-asserted-by":"publisher","first-page":"280","DOI":"10.9740\/mhc.2019.07.280","volume":"9","author":"JL McCarrell","year":"2019","unstructured":"McCarrell JL, Bailey TA, Duncan NA, Covington LP, Clifford KM, Hall RG, et al. A review of citalopram dose restrictions in the treatment of neuropsychiatric disorders in older adults. Ment Health Clin. 2019;9:280\u20136.","journal-title":"Ment Health Clin."},{"key":"707_CR106","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.1503\/jpn.130055","volume":"38","author":"M Hasnain","year":"2013","unstructured":"Hasnain M, Howland RH, Vieweg WVR. Escitalopram and QTc prolongation. J Psychiatry Neurosci. 2013;38:E11.","journal-title":"J Psychiatry Neurosci"},{"key":"707_CR107","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/YIC.0000000000000023","volume":"29","author":"C Sanchez","year":"2014","unstructured":"Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol. 2014;29:185\u201396.","journal-title":"Int Clin Psychopharmacol"},{"key":"707_CR108","doi-asserted-by":"crossref","unstructured":"Qirjazi E, McArthur E, Nash DM, Dixon SN, Weir MA, Vasudev A, et al. Risk of ventricular arrhythmia with citalopram and escitalopram: a population-based study. PloS One. 2016;11.","DOI":"10.1371\/journal.pone.0160768"},{"key":"707_CR109","unstructured":"ClinicalTrials.gov. Escitalopram treatment for BPSD in Alzheimer\u2019s disease in comparison to risperidone. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01119638. Accessed 20 Aug 2019."},{"key":"707_CR110","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1017\/S1041610211000743","volume":"23","author":"Y Barak","year":"2011","unstructured":"Barak Y, Plopski I, Tadger S, Paleacu D. Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer\u2019s disease: a randomized double-blind pilot study. Int Psychogeriatr. 2011;23:1515\u20139.","journal-title":"Int Psychogeriatr"},{"key":"707_CR111","doi-asserted-by":"publisher","first-page":"12559","DOI":"10.1523\/JNEUROSCI.0626-16.2016","volume":"36","author":"AS Berry","year":"2016","unstructured":"Berry AS, Shah VD, Baker SL, Vogel JW, O\u2019Neil JP, Janabi M, et al. Aging affects dopaminergic neural mechanisms of cognitive flexibility. J Neurosci. 2016;36:12559\u201369.","journal-title":"J Neurosci"},{"issue":"50","key":"707_CR112","doi-asserted-by":"publisher","first-page":"12559","DOI":"10.1523\/JNEUROSCI.0626-16.2016","volume":"36","author":"AS Berry","year":"2016","unstructured":"Berry AS, Shah VD, Baker SL, et al. Aging affects dopaminergic neural mechanisms of cognitive flexibility. J Neurosci. 2016;36(50):12559\u201369.","journal-title":"J Neurosci"},{"key":"707_CR113","unstructured":"US FDA. Novel drug approvals for 2015. http:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/novel-drug-approvals-2015. Accessed 27 Aug 2019."},{"key":"707_CR114","unstructured":"Lundbeck H. Otsuka and Lundbeck announce improvement of agitation symptoms related to Alzheimer\u2019s-type dementia following treatment with brexpiprazole relative to placebo. 2017.\u00a0https:\/\/investor.lundbeck.com\/news-releases\/news-release-details\/otsuka-and-lundbeck-announce-improvement-agitation-symptoms\/"},{"key":"707_CR115","doi-asserted-by":"crossref","unstructured":"Das S, Barmwal P, Winston AB, Mondal S, Saha I. Brexpiprazole: so far so good. 2016;6(1):39\u201354.","DOI":"10.1177\/2045125315614739"},{"key":"707_CR116","unstructured":"ClinicalTrials.gov. A 12-week extension trial to evaluate the safety and tolerability of brexpiprazole in the treatment of subjects with agitation associated with dementia of the Alzheimer\u2019s type. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03594123. Accessed 24 Aug 2019."},{"key":"707_CR117","doi-asserted-by":"crossref","unstructured":"Davis R, Dmitrienko A, Glass S, Kozauer S, Saillard J, Weingart M, et al. F46. Lumateperone (ITI-007): favorable safety profile in an open label safety switching study from standard-of-care antispychotic therapy in patients with schizophrenia. Schizophr Bull. 2018;44:S236\u20137.","DOI":"10.1093\/schbul\/sby017.577"},{"key":"707_CR118","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1007\/s00213-015-3922-1","volume":"232","author":"RE Davis","year":"2015","unstructured":"Davis RE, Vanover KE, Zhou Y, Bra\u0161i\u0107 JR, Guevara M, Bisuna B, et al. ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers. Psychopharmacology. 2015;232:2863\u201372.","journal-title":"Psychopharmacology"},{"key":"707_CR119","unstructured":"Intra-Cellular Therapies Inc. Intra-Cellular Therapies announces update on ITI-007-201 clinical trial for treatment of agitation in patients with probable Alzheimer\u2019s disease. https:\/\/ir.intracellulartherapies.com\/news-releases\/news-release-details\/intra-cellular-therapies-announces-update-iti-007-201-clinical. Accessed 24 Aug 2019."},{"key":"707_CR120","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1096\/fj.04-1575fje","volume":"18","author":"ET Tzavara","year":"2004","unstructured":"Tzavara ET, Bymaster FP, Davis RJ, Wade MR, Perry KW, Wess J, et al. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J. 2004;18:1410\u20132.","journal-title":"FASEB J."},{"key":"707_CR121","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0014-2999(96)00346-9","volume":"309","author":"H Kamei","year":"1996","unstructured":"Kamei H, Kameyama T, Nabeshima T. (+)-SKF-10,047 and dextromethorphan ameliorate conditioned fear stress via dopaminergic systems linked to phenytoin-regulated sigma 1 sites. Eur J Pharmacol. 1996;309:149\u201358.","journal-title":"Eur J Pharmacol"},{"key":"707_CR122","doi-asserted-by":"publisher","first-page":"89985","DOI":"10.1371\/journal.pone.0089985","volume":"9","author":"L Nguyen","year":"2014","unstructured":"Nguyen L, Robson MJ, Healy JR, Scandinaro AL, Matsumoto RR. Involvement of sigma-1 receptors in the antidepressant-like effects of dextromethorphan. PLoS One. 2014;9:89985.","journal-title":"PLoS One"},{"key":"707_CR123","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1254\/jphs.11R02CR","volume":"116","author":"E-J Shin","year":"2011","unstructured":"Shin E-J, Bach J-H, Lee SY, Kim JM, Lee J, Hong J-S, et al. Neuropsychotoxic and neuroprotective potentials of dextromethorphan and its analogs. J Pharmacol Sci. 2011;116:137\u201348.","journal-title":"J Pharmacol Sci."},{"key":"707_CR124","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.pharmthera.2016.04.010","volume":"164","author":"CP Taylor","year":"2016","unstructured":"Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. Pharmacology of dextromethorphan: Relevance to dextromethorphan\/quinidine (Nuedexta\u00ae) clinical use. Pharmacol Ther. 2016;164:170\u201382.","journal-title":"Pharmacol Ther"},{"issue":"7\u20138","key":"707_CR125","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/dta.1620","volume":"6","author":"H Morris","year":"2014","unstructured":"Morris H, Wallach J. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal. 2014;6(7\u20138):614\u201332.","journal-title":"Drug Test Anal."},{"key":"707_CR126","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/13543784.2017.1267726","volume":"26","author":"RP Garay","year":"2017","unstructured":"Garay RP, Grossberg GT. AVP-786 for the treatment of agitation in dementia of the Alzheimer\u2019s type. Expert Opin Investig Drugs. 2017;26:121\u201332.","journal-title":"Expert Opin Investig Drugs"},{"key":"707_CR127","unstructured":"Drugs@FDA. FDA-approved drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=021879. Accessed 16 Dec 2019."},{"key":"707_CR128","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jama.2015.10214","volume":"314","author":"JL Cummings","year":"2015","unstructured":"Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314:1242\u201354.","journal-title":"JAMA"},{"key":"707_CR129","unstructured":"Avanir Pharmaceuticals Inc. Avanir Pharmaceuticals announces accelerated development path for AVP-786 following successful pre-IND meeting with FDA. https:\/\/www.avanir.com\/press\/avanir-pharmaceuticals-announces-accelerated-development-path-avp-786-following-successful. Accessed 16 Dec 2019."},{"key":"707_CR130","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1527-3458.2006.00178.x","volume":"12","author":"LP Dwoskin","year":"2006","unstructured":"Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev. 2006;12:178\u2013207.","journal-title":"CNS Drug Rev"},{"key":"707_CR131","unstructured":"Axsome Therapeutics. About AXS-05. https:\/\/axsome.com\/axs-pipeline\/about-axs-05\/. Accessed 16 Dec 2019."},{"key":"707_CR132","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0074-7742(06)78003-5","volume":"78","author":"DC Javitt","year":"2007","unstructured":"Javitt DC. Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol. 2007;78:69\u2013108.","journal-title":"Int Rev Neurobiol"},{"key":"707_CR133","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00213-018-4877-9","volume":"235","author":"MA Mehta","year":"2018","unstructured":"Mehta MA, Schmechtig A, Kotoula V, McColm J, Jackson K, Brittain C, et al. Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects. Psychopharmacology. 2018;235:1875\u201386.","journal-title":"Psychopharmacology"},{"key":"707_CR134","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.biopsych.2015.03.016","volume":"78","author":"BJ Kinon","year":"2015","unstructured":"Kinon BJ, Millen BA, Zhang L, McKinzie DL. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry. 2015;78:754\u201362.","journal-title":"Biol Psychiatry"},{"key":"707_CR135","first-page":"53","volume":"27","author":"A Mechri","year":"2001","unstructured":"Mechri A, Saoud M, Khiari G, d\u2019Amato T, Dalery J, Gaha L. Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine. L\u2019Encephale. 2001;27:53\u20139.","journal-title":"L\u2019Encephale"},{"key":"707_CR136","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1124\/jpet.116.237859","volume":"361","author":"CC Felder","year":"2017","unstructured":"Felder CC, Schober DA, Tu Y, Quets A, Xiao H, Watt M, et al. Translational pharmacology of the metabotropic glutamate 2 receptor-preferring agonist LY2812223 in the animal and human brain. J Pharmacol Exp Ther. 2017;361:190\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"707_CR137","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1111\/bcp.13252","volume":"83","author":"J McColm","year":"2017","unstructured":"McColm J, Brittain C, Suriyapperuma S, Swanson S, Tauscher-Wisniewski S, Foster J, et al. Evaluation of single and multiple doses of a novel mGlu2 agonist, a potential antipsychotic therapy, in healthy subjects. Br J Clin Pharmacol. 2017;83:1654\u201367.","journal-title":"Br J Clin Pharmacol"},{"key":"707_CR138","first-page":"71","volume":"47","author":"S C\u00e9lanire","year":"2012","unstructured":"C\u00e9lanire S, Duvey G, Poli S, Rocher J-P. mGluR2 activators and mGluR5 blockers advancing in the clinic for major CNS disorders. Annu Rep Med Chem. 2012;47:71\u201388.","journal-title":"Annu Rep Med Chem."},{"key":"707_CR139","unstructured":"TVM Life Science Ventures VII announces investment in Mediti Pharma Inc. for the development of a novel treatment for Alzheimer\u2019s disease psychosis. 2016. https:\/\/www.tvm-lifescience.com\/tvm-life-science-ventures-vii-announces-investment-in-mediti-pharma-inc-for-the-development-of-a-novel-treatment-for-alzheimers-disease-psychosis\/. Accessed 16 Dec 2019."},{"key":"707_CR140","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/mp.2008.47","volume":"13","author":"P Burnet","year":"2008","unstructured":"Burnet P, Eastwood S, Bristow G, Godlewska B, Sikka P, Walker M, et al. D-amino acid oxidase (DAO) activity and expression are increased in schizophrenia. Mol Psychiatry. 2008;13:658\u201360.","journal-title":"Mol Psychiatry."},{"key":"707_CR141","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.neuropharm.2013.03.030","volume":"74","author":"Q Zhou","year":"2013","unstructured":"Zhou Q, Sheng M. NMDA receptors in nervous system diseases. Neuropharmacology. 2013;74:69\u201375.","journal-title":"Neuropharmacology"},{"issue":"1\u20132","key":"707_CR142","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s11064-016-1838-8","volume":"41","author":"H Sershen","year":"2016","unstructured":"Sershen H, Hashim A, Dunlop DS, Seckow RF, Cooper TB, et al. Modulating NMDA receptor function with D-amino acid oxidase inhibitors: understanding functional activity in PCP-treated mouse model. Neurochem Res. 2016;41(1\u20132):398\u2013408.","journal-title":"Neurochem Res"},{"key":"707_CR143","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.biopsych.2013.08.010","volume":"75","author":"C-H Lin","year":"2014","unstructured":"Lin C-H, Chen P-K, Chang Y-C, Chuo L-J, Chen Y-S, Tsai GE, et al. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry. 2014;75:678\u201385.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"707_CR144","first-page":"443","volume":"40","author":"Q Chen","year":"2015","unstructured":"Chen Q, Xiao EY, Goldman AL, Bharadwaj R, Healy K, et al. Poster session III Wednesday, December 9, 2015. Neuropsychopharmacology. 2015;40(1):443\u2013611.","journal-title":"Neuropsychopharmacology."},{"key":"707_CR145","unstructured":"Pipeline\u2014SyneuRx. http:\/\/www.syneurx.com\/en\/pipeline\/. Accessed 16 Dec 2019."},{"key":"707_CR146","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0079-6123(03)45003-6","volume":"145","author":"LA Volpicelli","year":"2004","unstructured":"Volpicelli LA, Levey AI. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog Brain Res. 2004;145:59\u201366.","journal-title":"Prog Brain Res"},{"key":"707_CR147","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fnmol.2018.00254","volume":"11","author":"G Leanza","year":"2018","unstructured":"Leanza G, Gulino R, Zorec R. Noradrenergic hypothesis linking neurodegeneration-based cognitive decline and astroglia. Front Mol Neurosci. 2018;11:254.","journal-title":"Front Mol Neurosci."},{"key":"707_CR148","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.neuroscience.2007.01.031","volume":"146","author":"P Szot","year":"2007","unstructured":"Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: evidence of compensatory changes. Neuroscience. 2007;146:471\u201380.","journal-title":"Neuroscience"},{"key":"707_CR149","doi-asserted-by":"crossref","unstructured":"Sharp SI, Ballard CG, Chen CPL-H, Francis PT. Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease. Am J Geriatr Psychiatry. 2007;15:435\u20137.","DOI":"10.1097\/01.JGP.0000237065.78966.1b"},{"key":"707_CR150","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1523\/JNEUROSCI.4265-05.2006","volume":"26","author":"P Szot","year":"2006","unstructured":"Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA. Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer\u2019s disease and dementia with Lewy bodies. J Neurosci. 2006;26:467\u201378.","journal-title":"J Neurosci"},{"key":"707_CR151","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/JGP.0b013e3181ab8c61","volume":"17","author":"LY Wang","year":"2009","unstructured":"Wang LY, Shofer JB, Rohde K, Hart KL, Hoff DJ, McFall YH, et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry. 2009;17:744\u201351.","journal-title":"Am J Geriatr Psychiatry."},{"key":"707_CR152","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jcgg.2015.06.001","volume":"7","author":"MJ Greve","year":"2016","unstructured":"Greve MJ, DesJarlais D, Ahmed I. Successful treatment of agitation and aggression with prazosin in an elderly patient with dementia and comorbid heart disease. J Clin Gerontol Geriatr. 2016;7:109\u201311.","journal-title":"J Clin Gerontol Geriatr."},{"issue":"Suppl. 6","key":"707_CR153","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2165\/00003495-198800356-00003","volume":"35","author":"PA van Zwieten","year":"1988","unstructured":"van Zwieten PA. Antihypertensive drugs interacting with alpha- and beta-adrenoceptors: a review of basic pharmacology. Drugs. 1988;35(Suppl. 6):6\u201319.","journal-title":"Drugs."},{"key":"707_CR154","unstructured":"The Binding Database. Compounds in cluster. http:\/\/www.bindingdb.org\/bind\/searchby_monomerids.jsp?monomerids=29568,50063906,50403647,50403649,50408679,50411350,50411351,50411352,50411353,50411354&title=10+similar+compounds+to+monomer+50122826. Accessed 24 Aug 2019."},{"key":"707_CR155","first-page":"875","volume":"241","author":"SB Jones","year":"1987","unstructured":"Jones SB, Smith JM, Jones AW, Bylund DB. Alpha-1 adrenergic receptor binding in aortas from rat and dog: comparison of [3H]prazosin and beta-iodo-[125I]-4-hydroxyphenyl-ethyl-aminomethyl-tetralone. J Pharmacol Exp Ther. 1987;241:875\u201381.","journal-title":"J Pharmacol Exp Ther"},{"key":"707_CR156","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40263-015-0270-y","volume":"29","author":"CS Liu","year":"2015","unstructured":"Liu CS, Chau SA, Ruthirakuhan M, Lanct\u00f4t KL, Herrmann N. Cannabinoids for the treatment of agitation and aggression in Alzheimer\u2019s disease. CNS Drugs. 2015;29:615\u201323.","journal-title":"CNS Drugs"},{"key":"707_CR157","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.neuropharm.2014.09.022","volume":"96","author":"S Rossi","year":"2015","unstructured":"Rossi S, Motta C, Musella A, Centonze D. The interplay between inflammatory cytokines and the endocannabinoid system in the regulation of synaptic transmission. Neuropharmacology. 2015;96:105\u201312.","journal-title":"Neuropharmacology"},{"key":"707_CR158","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3233\/JAD-141635","volume":"43","author":"G Bedse","year":"2015","unstructured":"Bedse G, Romano A, Lavecchia AM, Cassano T, Gaetani S. The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer\u2019s disease. J Alzheimers Dis. 2015;43:1115\u201336.","journal-title":"J Alzheimers Dis."},{"key":"707_CR159","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3233\/JAD-130137","volume":"35","author":"E Aso","year":"2013","unstructured":"Aso E, Juv\u00e9s S, Maldonado R, Ferrer I. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in A\u03b2PP\/PS1 mice. J Alzheimers Dis. 2013;35:847\u201358.","journal-title":"J Alzheimers Dis."},{"key":"707_CR160","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fnins.2017.00030","volume":"11","author":"T Cassano","year":"2017","unstructured":"Cassano T, Calcagnini S, Pace L, De Marco F, Romano A, Gaetani S. Cannabinoid receptor 2 signaling in neurodegenerative disorders: from pathogenesis to a promising therapeutic target. Front Neurosci. 2017;11:30.","journal-title":"Front Neurosci."},{"key":"707_CR161","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.bbr.2014.01.037","volume":"263","author":"FC Vilela","year":"2014","unstructured":"Vilela FC, Giusti-Paiva A. Cannabinoid receptor agonist disrupts behavioral and neuroendocrine responses during lactation. Behav Brain Res. 2014;263:190\u20137.","journal-title":"Behav Brain Res"},{"key":"707_CR162","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","volume":"153","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199\u2013215.","journal-title":"Br J Pharmacol"},{"issue":"23","key":"707_CR163","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1212\/WNL.0000000000001675","volume":"84","author":"GAH Van den Elsen","year":"2015","unstructured":"Van den Elsen GAH, Ahmed AIA, Verkes R-J, Kramers C, Feuth T, et al. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia. Neurology.\u00a02015;84(23):2338\u201346.","journal-title":"Neurology"},{"key":"707_CR164","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.jagp.2015.07.011","volume":"23","author":"GAH van den Elsen","year":"2015","unstructured":"van den Elsen GAH, Ahmed AIA, Verkes R-J, Feuth T, van der Marck MA, Olde Rikkert MGM. Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized controlled trial. Am J Geriatr Psychiatry. 2015;23:1214\u201324.","journal-title":"Am J Geriatr Psychiatry."},{"key":"707_CR165","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jagp.2012.11.022","volume":"22","author":"MR Woodward","year":"2014","unstructured":"Woodward MR, Harper DG, Stolyar A, Forester BP, Ellison JM. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. Am J Geriatr Psychiatry. 2014;22:415\u20139.","journal-title":"Am J Geriatr Psychiatry."},{"key":"707_CR166","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D","volume":"12","author":"L Volicer","year":"1997","unstructured":"Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer\u2019s disease. Int J Geriatr Psychiatry. 1997;12:913\u20139.","journal-title":"Int J Geriatr Psychiatry."},{"issue":"4","key":"707_CR167","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s00213-006-0343-1","volume":"185","author":"S Walther","year":"2006","unstructured":"Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology. 2006;185(4):524\u20138.","journal-title":"Psychopharmacology"},{"key":"707_CR168","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00391-007-0420-z","volume":"40","author":"R Mahlberg","year":"2007","unstructured":"Mahlberg R, Walther S. Actigraphy in agitated patients with dementia: monitoring treatment outcomes. Z Gerontol Geriatr. 2007;40:178\u201384.","journal-title":"Z Gerontol Geriatr"},{"key":"707_CR169","doi-asserted-by":"crossref","unstructured":"Walther S, Sch\u00fcpbach B, Seifritz E, Homan P, Strik W. Randomized, controlled crossover trial of dronabinol, 2.5\u00a0mg, for agitation in 2 patients with dementia. J Clin Psychopharmacol. 2011;31:256\u20138.","DOI":"10.1097\/JCP.0b013e31820e861c"},{"issue":"19","key":"707_CR170","doi-asserted-by":"publisher","first-page":"6996","DOI":"10.1021\/jm100641g","volume":"52","author":"SP Nikas","year":"2010","unstructured":"Nikas SP, Alapafuja SO, Papanastasiou I, Paronis CA, Shukla VG. Novel 1\u2032,1\u2032-chain substituted hexahydrocannabinols: 9\u03b2-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist. J Med Chem. 2010;52(19):6996\u20137010.","journal-title":"J Med Chem"},{"key":"707_CR171","first-page":"142","volume":"10","author":"S Amanullah","year":"2013","unstructured":"Amanullah S, MacDougall K, Sweeney N, Coffin J, Cole J. Synthetic cannabinoids in dementia with agitation: case studies and literature review. Clin Neuropsychiatry. 2013;10:142\u20137.","journal-title":"Clin Neuropsychiatry."},{"key":"707_CR172","doi-asserted-by":"crossref","first-page":"413","DOI":"10.31887\/DCNS.2007.9.4\/nkogan","volume":"9","author":"NM Kogan","year":"2007","unstructured":"Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialog Clin Neurosci. 2007;9:413\u201330.","journal-title":"Dialog Clin Neurosci."},{"key":"707_CR173","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12877-017-0653-7","volume":"17","author":"KM Blytt","year":"2017","unstructured":"Blytt KM, Bjorvatn B, Husebo B, Flo E. Clinically significant discrepancies between sleep problems assessed by standard clinical tools and actigraphy. BMC Geriatr. 2017;17:253.","journal-title":"BMC Geriatr."},{"key":"707_CR174","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1176\/appi.ajp.2008.07121882","volume":"165","author":"HJ Cho","year":"2008","unstructured":"Cho HJ, Lavretsky H, Olmstead R, Levin MJ, Oxman MN, Irwin MR. Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry. 2008;165:1543\u201350.","journal-title":"Am J Psychiatry"},{"key":"707_CR175","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0167-4943(00)00068-6","volume":"31","author":"J Cohen-Mansfield","year":"2000","unstructured":"Cohen-Mansfield J, Garfinkel D, Lipson S. Melatonin for treatment of sundowning in elderly persons with dementia: a preliminary study. Arch Gerontol Geriatr. 2000;31:65\u201376.","journal-title":"Arch Gerontol Geriatr"},{"key":"707_CR176","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2147\/NDT.S3201","volume":"4","author":"S Cakir","year":"2008","unstructured":"Cakir S, Kulaksizoglu IB. The efficacy of mirtazapine in agitated patients with Alzheimer\u2019s disease: a 12-week open-label pilot study. Neuropsychiatr Dis Treat. 2008;4:963\u20136.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"707_CR177","first-page":"215","volume":"24","author":"CR Dolder","year":"2012","unstructured":"Dolder CR, Nelson MH, Iler CA. The effects of mirtazapine on sleep in patients with major depressive disorder. Ann Clin Psychiatry. 2012;24:215\u201324.","journal-title":"Ann Clin Psychiatry"},{"key":"707_CR178","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/sj.npp.1300923","volume":"31","author":"DA Schmid","year":"2006","unstructured":"Schmid DA, Wichniak A, Uhr M, Ising M, Brunner H, Held K, et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology. 2006;31:832\u201344.","journal-title":"Neuropsychopharmacology."},{"key":"707_CR179","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1527-3458.2001.tb00198.x","volume":"7","author":"SA Anttila","year":"2001","unstructured":"Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7:249\u201364.","journal-title":"CNS Drug Rev"},{"key":"707_CR180","doi-asserted-by":"publisher","first-page":"4526","DOI":"10.1016\/j.bmc.2006.02.029","volume":"14","author":"M Van der Mey","year":"2006","unstructured":"Van der Mey M, Windhorst AD, Klok RP, Herscheid JDM, Kennis LE, Bischoff F, et al. Synthesis and biodistribution of [11C]R107474, a new radiolabeled alpha2-adrenoceptor antagonist. Bioorg Med Chem. 2006;14:4526\u201334.","journal-title":"Bioorg Med Chem"},{"key":"707_CR181","doi-asserted-by":"crossref","unstructured":"Buskova J, Busek P, Nevsimalova S. Gabapentin in the treatment of dementia-associated nocturnal agitation. Med Sci Monit. 2011;17:CS149\u201351.","DOI":"10.12659\/MSM.882114"},{"key":"707_CR182","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ebiom.2019.03.047","volume":"42","author":"DS Reddy","year":"2019","unstructured":"Reddy DS. An enigmatic role of tonic inhibition in gabapentin therapy. EBioMedicine. 2019;42:14\u20135.","journal-title":"EBioMedicine."},{"key":"707_CR183","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1113\/JP272262","volume":"594","author":"AC Dolphin","year":"2016","unstructured":"Dolphin AC. Voltage-gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacology. J Physiol. 2016;594:5369\u201390.","journal-title":"J Physiol"},{"issue":"6","key":"707_CR184","first-page":"10","volume":"44","author":"CP Taylor","year":"1994","unstructured":"Taylor CP. Emerging perspectives on the mechanism of action of gabapentin. Neurology. 1994;44(6):10\u20136.","journal-title":"Neurology."},{"issue":"3","key":"707_CR185","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1177\/070674379804300315","volume":"43","author":"G Chouinard","year":"1998","unstructured":"Chouinard G, Beauclair L, Belanger MC. Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry. 1998;43(3):305.","journal-title":"Can J Psychiatry"},{"issue":"5","key":"707_CR186","first-page":"16","volume":"54","author":"M Sammaritano","year":"2000","unstructured":"Sammaritano M, Sherwin A. Effect of anticonvulsants on sleep. Neurology. 2000;54(5):16\u201324.","journal-title":"Neurology."},{"issue":"1","key":"707_CR187","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1176\/jnp.12.1.40","volume":"12","author":"DM Roane","year":"2000","unstructured":"Roane DM, Deinberg TE, Meckler L, Miner CR, Scicutella A. Treatment of dementia-associated agitation with gabapentin. J Neuropsychiatry Clin Neurosci. 2000;12(1):40\u20133.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"3","key":"707_CR188","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2165\/00002512-200825030-00002","volume":"25","author":"Y Kim","year":"2008","unstructured":"Kim Y, Wilkins KM, Tampl RR. Use of gabapentin in the treatment of behavioural and psychological symptoms of dementia. Drugs Aging. 2008;25(3):187\u201396.","journal-title":"Drugs Aging"},{"key":"707_CR189","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1503\/cmaj.170193","volume":"189","author":"PA Rochon","year":"2017","unstructured":"Rochon PA, Vozoris N, Gill SS. The harms of benzodiazepines for patients with dementia. CMAJ. 2017;189:517\u20138.","journal-title":"CMAJ"},{"key":"707_CR190","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pbb.2015.07.014","volume":"137","author":"L Zvejniece","year":"2015","unstructured":"Zvejniece L, Vavers E, Svalbe B, Veinberg G, Rizhanova K, Liepins V, et al. R-phenibut binds to the \u03b12-\u03b4 subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects. Pharmacol Biochem Behav. 2015;137:23\u20139.","journal-title":"Pharmacol Biochem Behav"},{"key":"707_CR191","unstructured":"ClinicalTrials.gov. Citalopram for agitation in Alzheimer\u2019s disease. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00898807. Accessed 16 Dec 2019."},{"key":"707_CR192","unstructured":"ClinicalTrials.gov. Safety and tolerability study of two fixed-doses of brexpiprazole in the treatment of subjects with agitation associated with dementia of the Alzheimer\u2019s type. .https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01862640. Accessed 16 Dec 2019."},{"key":"707_CR193","unstructured":"ClinicalTrials.gov. Safety and tolerability study of flexible dosing of brexpiprazole in the treatment of subjects with agitation associated with dementia of the Alzheimer\u2019s type. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01922258?term=NCT01922258&draw=2&rank=1. Accessed 16 Dec 2019."},{"key":"707_CR194","unstructured":"ClinicalTrials.gov. Delta-THC in dementia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01608217. Accessed 16 Dec 2019."},{"key":"707_CR195","unstructured":"ClinicalTrials.gov. Delta-THC in behavioral disturbances in dementia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01302340. Accessed 16 Dec 2019."},{"key":"707_CR196","unstructured":"ClinicalTrials.gov. Efficacy, safety and tolerability study of AVP-923 (dextromethorphan\/quinidine) for treatment of symptoms of agitation in Alzheimer\u2019s patients. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01584440. Accessed 16 Dec 2019."},{"key":"707_CR197","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1021\/jm058225d","volume":"48","author":"R Morphy","year":"2005","unstructured":"Morphy R, Rankovic Z. Designed multiple ligands: an emerging drug discovery paradigm. J Med Chem. 2005;48:6523\u201343.","journal-title":"J Med Chem"},{"issue":"15","key":"707_CR198","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S1359-6446(04)03163-0","volume":"9","author":"R Morphy","year":"2004","unstructured":"Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today. 2004;9(15):641\u201351.","journal-title":"Drug Discov Today."},{"key":"707_CR199","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1021\/jm401895u","volume":"57","author":"M Ko\u0142aczkowski","year":"2014","unstructured":"Ko\u0142aczkowski M, Marcinkowska M, Bucki A, Paw\u0142owski M, Mitka K, Ja\u015bkowska J, et al. Novel arylsulfonamide derivatives with 5-HT6\/5-HT7 receptor antagonism targeting behavioral and psychological symptoms of dementia. J Med Chem. 2014;57:4543\u201357.","journal-title":"J Med Chem"},{"key":"707_CR200","doi-asserted-by":"publisher","first-page":"7483","DOI":"10.1021\/acs.jmedchem.7b00839","volume":"60","author":"A Bucki","year":"2017","unstructured":"Bucki A, Marcinkowska M, \u015aniecikowska J, Wi\u0119ckowski K, Paw\u0142owski M, G\u0142uch-Lutwin M, et al. Novel 3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole-based multifunctional ligands with antipsychotic-like, mood-modulating, and procognitive activity. J Med Chem. 2017;60:7483\u2013501.","journal-title":"J Med Chem"},{"key":"707_CR201","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ejmech.2014.12.045","volume":"92","author":"M Ko\u0142aczkowski","year":"2015","unstructured":"Ko\u0142aczkowski M, Marcinkowska M, Bucki A, \u015aniecikowska J, Paw\u0142owski M, Kazek G, et al. Novel 5-HT6 receptor antagonists\/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia. Eur J Med Chem. 2015;92:221\u201335.","journal-title":"Eur J Med Chem"},{"key":"707_CR202","unstructured":"Ko\u0142aczkowski M, Marcinkowska M, Bucki A, Paw\u0142owski M, Krukowski A, Rusiecki R, et al. Sulphonamide derivatives of alicyclic amines for the treatment of central nervous system diseases. Patent WO2013001505, 2013."},{"key":"707_CR203","unstructured":"Ko\u0142aczkowski M, Marcinkowska M, Bucki A, Paw\u0142owski M, Kazek G, Bednarski M, et al. Indoleamine derivatives for the treatment of central nervous system diseases. Patent WO2013001499, 2013."},{"key":"707_CR204","first-page":"183","volume":"10","author":"DJ Foster","year":"2014","unstructured":"Foster DJ, Choi DL, Conn PJ, Rook JM. Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer\u2019s disease and schizophrenia. Neuropsychiatr Dis Treat. 2014;10:183\u201391.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"707_CR205","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1021\/cn500128b","volume":"5","author":"M Bubser","year":"2014","unstructured":"Bubser M, Bridges TM, Dencker D, Gould RW, Grannan M, Noetzel MJ, et al. Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents. ACS Chem Neurosci. 2014;5:920\u201342.","journal-title":"ACS Chem Neurosci."},{"issue":"6","key":"707_CR206","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1021\/acschemneuro.6b00278","volume":"8","author":"EP Lebois","year":"2017","unstructured":"Lebois EP, Schroeder JP, Esparza TJ, Bridges TM, Lindsley CW, et al. Disease-modifying effects of M1 muscarinic acetylcholine receptor activation in an Alzheimer\u2019s disease mouse model. ACS Chem Neurosci. 2017;8(6):1177\u201387.","journal-title":"ACS Chem Neurosci."},{"key":"707_CR207","unstructured":"Partnered Programs\u2014Sosei Heptares. https:\/\/soseiheptares.com\/our-pipeline\/rd-pipeline\/partnered-programs.html. Accessed 16 Dec 2019."},{"key":"707_CR208","first-page":"20","volume":"127","author":"M R\u00f6sler","year":"2002","unstructured":"R\u00f6sler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl. 2002;127:20\u201336.","journal-title":"Int J Clin Pract Suppl."},{"key":"707_CR209","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/B978-0-12-386467-3.00010-8","volume":"100","author":"O Weinreb","year":"2011","unstructured":"Weinreb O, Amit T, Bar-Am O, Youdim MB. A novel anti-Alzheimer\u2019s disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor. Int Rev Neurobiol. 2011;100:191\u2013215.","journal-title":"Int Rev Neurobiol"},{"key":"707_CR210","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2174\/138945012799499794","volume":"13","author":"O Weinreb","year":"2012","unstructured":"Weinreb O, Amit T, Bar-Am O, Youdim MBH. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer\u2019s disease treatment. Curr Drug Targets. 2012;13:483\u201394.","journal-title":"Curr Drug Targets"},{"issue":"3","key":"707_CR211","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s00213-001-0978-x","volume":"160","author":"M Weinstock","year":"2002","unstructured":"Weinstock M, Poltyrev T, Bejar C, Youdim MB. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology. 2002;160(3):318\u201324.","journal-title":"Psychopharmacology"},{"key":"707_CR212","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/14728214.2017.1293651","volume":"22","author":"A Calhoun","year":"2017","unstructured":"Calhoun A, Ko J, Grossberg GT. Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer\u2019s disease. Expert Opin Emerg Drugs. 2017;22:101\u20135.","journal-title":"Expert Opin Emerg Drugs."},{"key":"707_CR213","unstructured":"R&D Department. Adamed. https:\/\/adamed.com.pl\/en\/rd-department. Accessed 16 Dec 2019."},{"key":"707_CR214","doi-asserted-by":"crossref","unstructured":"Wu C-S, Wang S-C, Gau SS-F, Tsai H-J, Cheng Y-C. Association of stroke with the receptor-binding profiles of antipsychotics-a case-crossover study. Biol Psychiatry. 2013;73:414\u201321.","DOI":"10.1016\/j.biopsych.2012.07.006"},{"key":"707_CR215","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1136\/bmj.a1227","volume":"337","author":"IJ Douglas","year":"2008","unstructured":"Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ. 2008;337:1227.","journal-title":"BMJ"},{"key":"707_CR216","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.biopha.2017.06.008","volume":"93","author":"P Pa\u015bko","year":"2017","unstructured":"Pa\u015bko P, Rodacki T, Domaga\u0142a-Rodacka R, Palimonka K, Marcinkowska M, Owczarek D. Second generation H1\u2014antihistamines interaction with food and alcohol: a systematic review. Biomed Pharmacother. 2017;93:27\u201339.","journal-title":"Biomed Pharmacother"},{"key":"707_CR217","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.psc.2017.05.010","volume":"40","author":"A Aftab","year":"2017","unstructured":"Aftab A, Shah AA. Behavioral emergencies: special considerations in the geriatric psychiatric patient. Psychiatr Clin North Am. 2017;40:449\u201362.","journal-title":"Psychiatr Clin North Am"},{"key":"707_CR218","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40360-017-0157-2","volume":"18","author":"B Pfister","year":"2017","unstructured":"Pfister B, Jonsson J, Gustafsson M. Drug-related problems and medication reviews among old people with dementia. BMC Pharmacol Toxicol. 2017;18:52.","journal-title":"BMC Pharmacol Toxicol."},{"key":"707_CR219","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/2042098612454283","volume":"3","author":"S Nachimuthu","year":"2012","unstructured":"Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf. 2012;3:241\u201353.","journal-title":"Ther Adv Drug Saf."},{"key":"707_CR220","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1046\/j.1540-8167.2004.03534.x","volume":"15","author":"RR Fenichel","year":"2004","unstructured":"Fenichel RR, Malik M, Antzelevitch C, Sanguinetti M, Roden DM, Priori SG, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol. 2004;15:475\u201395.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"707_CR221","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/j.2051-5545.2008.tb00154.x","volume":"7","author":"A \u00dc\u00e7ok","year":"2008","unstructured":"\u00dc\u00e7ok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry. 2008;7:58\u201362.","journal-title":"World Psychiatry."},{"key":"707_CR222","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1080\/13543784.2016.1193155","volume":"25","author":"RP Garay","year":"2016","unstructured":"Garay RP, Citrome L, Grossberg GT, Cavero I, Llorca P-M. Investigational drugs for treating agitation in persons with dementia. Expert Opin Investig Drugs. 2016;25:973\u201383.","journal-title":"Expert Opin Investig Drugs"},{"key":"707_CR223","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1586\/14737175.2016.1155453","volume":"16","author":"R Magierski","year":"2016","unstructured":"Magierski R, Sobow T. Serotonergic drugs for the treatment of neuropsychiatric symptoms in dementia. Expert Rev Neurother. 2016;16:375\u201387.","journal-title":"Expert Rev Neurother"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00707-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-020-00707-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00707-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T14:39:39Z","timestamp":1722436779000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-020-00707-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":223,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["707"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00707-7","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,12]]},"assertion":[{"value":"12 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by the National Science Center of Poland (Grant DEC-2014\/15\/D\/NZ7\/01789) and National Center for Research and Development (Grant POIR.01.01.01-00-0108\/17). The open access has been sponsored by Jagiellonian University, Krak\u00f3w, Poland.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Marcin Ko\u0142aczkowski and Joanna \u015aniecikowska are employees of Adamed Pharma S.A. Monika Marcinkowska, Nikola Fajkis, Pawe\u0142 Pa\u015bko, and Weronika Franczyk have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in this article apart from those disclosed. No writing assistance was utilized in the production of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}